Drug intelligence / Profile preview

MQI-181

Development stage: Preclinical
Lead developer: Mabqi
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

**MQI-181** is a pH-sensitive antibody-drug conjugate (ADC) in preclinical development for hematology-oncology indications, particularly lymphoma and other blood cancers. Developed by Mabqi SAS, it represents a novel tumor-specific immunotherapy leveraging pH sensitivity to enhance selectivity and reduce off-target toxicity, with in vivo data demonstrating antitumor activity. The program is open for partnering and poised for further advancement.[1][3][5][7]

Other names: MQI 181MQI181MQI-181

Targets

CD30 (CD30 antigen)

Beyond the preview

Go deeper on MQI-181.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MQI-181.

Explore the full profile